Immuno-oncology has revolutionized cancer treatment and has opened up new opportunities for developing vaccination methods. DNA-based cancer vaccines have emerged as a promising approach to activating the bodily immune system against cancer. Plasmid DNA immunizations have shown a favorable safety profile and there occurs induction of generalized as well as tailored immune responses in preclinical and early-phase clinical experiments. However, these vaccines have notable limitations in immunogenicity and heterogeneity and these require refinements. DNA vaccine technology has been focusing on improving vaccine efficacy and delivery, with parallel developments in nanoparticle-based delivery systems and gene-editing technologies such as CRISPR/Cas9. This approach has showcased great promise in enhancing and tailoring the immune response to vaccination. Strategies to enhance the efficacy of DNA vaccines include the selection of appropriate antigens, optimizing insertion in a plasmid, and studying combinations of vaccines with conventional strategies and targeted therapies. Combination therapies have attenuated immunosuppressive activities in the tumor microenvironment and enhanced the capability of immune cells. This review provides an overview of the current framework of DNA vaccines in oncology and focuses on novel strategies, including established combination therapies and those still under development.The challenges that oncologists, scientists, and researchers need to overcome to establish DNA vaccines as an avant-garde approach to defeating cancer, are also emphasized. The clinical implications of the immunotherapeutic approaches and the need for predictive biomarkers have also been reviewed upon. We have also tried to extend the role of Neutrophil extracellular traps (NETs) to the DNA vaccines. The clinical implications of the immunotherapeutic approaches have also been reviewed upon. Ultimately, refining and optimizing DNA vaccines will enable harnessing the immune system's natural ability to recognize and eliminate cancer cells, leading the world towards a revolution in cancer cure.
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
He, Jide
Wu, Jialong
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Wu, Jialong
Li, Ziang
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Li, Ziang
Zhao, Zhenkun
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Zhao, Zhenkun
Qiu, Lei
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Qiu, Lei
Zhu, Xuehua
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Zhu, Xuehua
Liu, Zenan
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Liu, Zenan
Xia, Haizhui
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Xia, Haizhui
Hong, Peng
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Hong, Peng
Yang, Jianling
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Inst Med Innovat & Res, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Yang, Jianling
Ni, Ling
论文数: 0引用数: 0
h-index: 0
机构:
Tsinghua Univ, Inst Immunol, Med Res Bldg, Beijing, Peoples R China
Tsinghua Univ, Sch Med, Med Res Bldg, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Ni, Ling
Lu, Jian
论文数: 0引用数: 0
h-index: 0
机构:
Peking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
Peking Univ, State Key Lab Nat & Biomimet Drugs, Beijing, Peoples R ChinaPeking Univ Third Hosp, Dept Urol, Beijing, Peoples R China
机构:
Rush Univ, Div Hematol Oncol & Cell Therapy, Sect Med Oncol, Med Ctr, Chicago, IL 60612 USARush Univ, Div Hematol Oncol & Cell Therapy, Sect Med Oncol, Med Ctr, Chicago, IL 60612 USA